Connect with us

BUSINESS

This is Your Brain on CBD

Published

on

There is no question about it, the endocannabinoid system is a powerful player on the playing field of human physiology. And CBD and other exogenous cannabinoids can impact this playing field in a wide variety of interesting and important ways.

Perhaps some of the most important of these impacts can be found in the human brain. Most centrally, there are two critical receptors that make up this system: the CB1 and CB2 receptors.

To understand how they play a role in signaling the activity of neuronal cells in the brain, we need to understand more about how these receptors are integrated into the brain, and how the brain works by chemical signaling.

Understanding Chemical Signaling in the Brain

One of the most important features found in the human body is the action of the neurotransmitters. Neurotransmitters are signaling molecules that play a role in what is essentially the information technology network of the human body.

Neurotransmitters interface with receptors in the synapses of neurons. The chemical signal – the neurotransmitter – is something like a coded message that its proper receptor is able to decode. But the messages are often quite simple and essentially boil down to “go”, “stop”, and “turnaround”.

Respectively, these refer to agonists, antagonists, and inverse antagonists. Each of these plays an important role, and something of how they work should be relatively self-evident as we have described the situation above.

CBD and its Impact on CB1 and CB2 Receptors

CBD is something called a negative allosteric modulator with respect to the CB1 receptor, essentially having the effect of an antagonist (red light).

THC, on the other hand, is what’s known as an Orthosteric modulator. This is an agonist.

In brain cells, this type of function impacts how neurons respond to other signals from neurotransmitters. As noted above, each neuron has many different types of receptors that all act as decoding ports for the coded messages that fit their description.

As CBD antagonizes the CB1 receptor, it deemphasizes the importance of that receptor, thus increasing the importance of the other receptors, which then increase their impact on the functioning of the neuron.

According to research, this facilitates the overall functionality of the neuron, thereby promoting efficient brain function.

The CB2 receptors are more focused on functionality within the immune system. CBD helps the immune responses of the neurons, which also improves the overall functionality of the brain.

In addition, CBD is an agonist for serotonin receptors. In other words, CBD mimics the effect that serotonin produces, emphasizing positive mood and feelings of satisfaction.

This is particularly important for those suffering from depression and anxiety, which represent a serotonin deficiency. CBD can step into that role and rebalance the system. And, according to research of both an anecdotal and clinical nature, it can do so with absolutely no side effects at all.

While there remains plenty of research to conduct for scientists in the medical sciences and neurosciences, the data already compiled presents a very compelling case for a brain on CBD.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Aleafia Health Inc (OTCMKTS: ALEAF) Hosts Two-Day Conference With Retailer Harvest Party On Adult-use Momentum

Published

on

Aleafia Health Inc (OTCMKTS: ALEAF) was in the news again. The group had recently hosted its second annual adult-use retailer harvest party.

Here’s more about the recently hosted two-day event

The event was hosted at the group’s outdoor cultivation facility. It had in attendance more than 300 cannabis store owners, managers, budtenders, and industry leaders. As part of the two-day event, retailer tours of Port Perry’s 86 acre outdoor site were also hosted. In addition, participants of the two-day conference were allowed to attend and participate in the series of educational sessions hosted a part of the event. Participants of the educational sessions learned about the various methods of cultivation that the group adopts. Participants also got a glimpse of how Aleafia Health Inc has built its thriving portfolio.

Offering a behind-the-scenes scenes glimpse to attendees was a privilege for Geoffrey Benic, CEO of Aleafia Health Inc.

The CEO of Aleafia Health Inc, Geoffrey Benic, shared his thoughts on the recently hosted two-day event. He expressed being happy to offer a behind-the-scenes glimpse to attendees of the two-day conference. The cannabis company successfully generated a solid and robust engagement in the cannabis retailers in the market through the two-day event. Benic added that he is happy that the group successfully strengthened its market share, besides being able to build a lucrative customer base for the group’s Sunday Market brand family.

Adult-use cannabis net revenue during 2Q 2021 spiked 93%

Aleafia Health Inc has one more reason to be happy about, sources share.  According to the financial statement that the group issued, it has come to light that the corporate house has reported a 93% spike in income in 2Q 2021 generated from adult-use cannabis, which is reportedly a thriving sector. Furthermore, when probed on the reason for growth at this pace, it has come to light that the Divvy brand, an everyday cannabis brand, is one of the significant contributors to a spike in the adult-use cannabis net revenue during 2Q 2021.

Aleafia Health Inc is one of the leading vertically integrated licensed Canadian cannabis groups that offer health and wellness services. The corporate house has an international footprint with a presence in Germany and Australia.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

VIVO Cannabis Inc (OTCMKTS: VVCIF) Inks Deal A With Delta 9 Cannabis Inc (OTCMKTS: DLTNF) To Sell Its Products on the VIVO Cannabis Inc e-commerce Platform

Published

on

VIVO Cannabis Inc (OTCMKTS: VVCIF) has announced that the group has inked an ambitious partnership with Delta 9 Cannabis Inc (OTCMKTS: DLTNF). With the partnership on paper, VIVO Cannabis Inc is going to sell products of Delta 9 Cannabis Inc on its e-commerce platform.

Both the companies have received their respective licenses in 2013 and 2014 

Both companies; VIVO Cannabis Inc and Delta 9 Cannabis Inc have received their respective licenses from Health Canada. The two groups were granted the necessary licenses in anywhere between late 2013 and early 2014 by the Canadian authority. According to source who are monitoring the developments in the cannabis industry in Canada, VIVO Cannabis Inc and Delta 9 Cannabis Inc are the two longest running cannabis companies, with Health Canada licenses to their credit.

Information about the partnership 

The partnership will pave the way for VIVO Cannabis Inc to hand-pick and purchase products from the Delta 9 Cannabis Inc portfolio. The company will purchase and sell Delta 9 cannabis dried flower products. Beneficiaries include medical patients of the Canna Farms’. The products will be sold directly to the patients. By doing so, VIVO Cannabis Inc, on the one hand will successfully strengthen its product portfolio by expanding the options of brand the group offers and on the other hand, the cannabis company is giving its medical customers the option of brands to choose from. According to numbers that are shared by the company, the Canna Farms’ has as many as 20,000-odd active patients in the medical category who depend on the group’s medical solutions.

Delta 9 Cannabis Inc is happy that its products are available nationally

Delta 9 Cannabis Inc is more than happy that the group’s products will be available nationally. The Founder and Chief Executive Officer of Delta 9 Cannabis Inc, John Arbuthnot, went on record and expressed that he is excited that the group’s craft products have a national presence through one of the leaders in the medical cannabis segment. Furthermore, the Founder and Chief Executive Officer of the group added that Delta 9’s small batch of hand trimmed strains, are a perfect match for products that are sold under the Canna Farms’ banner.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Trulieve Cannabis Corp (OTCMKTS: TCNNF) Announces That The Group Has Successfully Closed 8% Senior Secured Notes That Are Due In 2026

Published

on

Trulieve Cannabis Corp (OTCMKTS: TCNNF) has announced that the group has successfully closed 8% of senior secured notes due in 2026. The group earlier reported about the previous closure. However, the proceeds were successfully carried out recently.

The value of the overall proceeds is $350.0 million

A source who is aware of the development shared that the overall value of the proceeds is $350.0 million. Furthermore, it is learned that the Notes were issued at 100% of their respective face value. It is known that the outstanding senior Notes of the group will mature in 2024. Those who own the Note are eligible for an interest rate of 8%. The respective interest is payable in multiple options. There is an option to redeem the interest amount annually, semi-annually, or the claim can be paid in equal installments till the date of maturity. It has come to light that October 6, 2026, is when the Notes will mature.

Furthermore, the Notes owner can redeem the Notes as a whole, in parts, during specific time intervals. For example, if the Notes owner wants to hold on to them, this can be done, and in this situation, the Notes can be redeemed after October 6, 2023, which is the maturity date. The price that is prescribed as redemption cost will be what the Note owner is eligible to receive.

Canaccord Genuity Corp. played the role of individual bookrunner

A source who is aware of the development shared that agency Canaccord Genuity Corp. played the role of an individual agent and book-runner. In a bid to have the Notes listed on the Canadian Securities Exchange (the CSE), Trulieve Cannabis Corp, completed all the legal formalities and adhered to the prescribed procedures. Accordingly, the four-month hold period is also followed as per the Canadian statutory.

Trulieve Cannabis Corp has closed on the $350 million debt issuance

Trulieve Cannabis Corp has closed on the $350 million debt issuance. This CEO of the group confirmed the news. The CEO of Trulieve Cannabis Corp, Kim Rivers, said that the strength in the capital market gives the corporate house access to capital which will act as a catalyst for the ambitious growth plans for the group. Rivers added that the corporate house is working towards achieving its futuristic goals.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories